Atavistik Bio Raises $60m For Metabolic Disease, Cancer Drug Discovery
Acting CEO Comes From Peloton; President/CSO From Blueprint, Agios
The preclinical start-up is identifying allosteric binders that can inhibit or activate metabolic proteins. Atavistik will focus on genetically defined diseases then test its candidates in broader populations.
